Aura Biosciences is a leading brand dedicated to the development of innovative cancer therapies. They specialize in creating virus-like drug conjugates (VDCs) that target and treat a wide range of solid tumor types. With a mission to establish a new standard of care in oncology, Aura Biosciences is committed to delivering meaningful therapeutic benefits to patients in need.

Their primary focus is on ocular and urologic oncology, particularly tumors with high unmet medical needs. Their flagship VDC candidate, belzupacap sarotalocan (bel-sar), is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease that currently lacks approved drugs. Additionally, Aura Biosciences is exploring the potential of bel-sar in other ocular oncology indications, including choroidal metastasis.

Recognizing the broad tumor targeting capabilities of their VDCs, Aura Biosciences has also initiated a clinical program for non-muscle invasive bladder cancer (NMIBC), their first non-ocular solid tumor indication. With a world-class leadership team and a robust pipeline of therapeutic candidates, Aura Biosciences is at the forefront of revolutionizing cancer treatment. They are driven by a passion for science and a deep commitment to improving the lives of cancer patients